AI Can Help Patients Get Prostate Cancer Drug That Cuts Death Risk By Half
Scientists have developed an artificial intelligence (AI) test that can predict which men with prostate cancer will benefit most from a drug that reduces the risk of dying. The life-extending drug called abiraterone has been called a 'gamechanger' treatment for the disease, but some countries are not offering it to men whose disease has not spread yet.
The new AI test, built by a team from the US, UK and Switzerland, shows which men would most likely benefit from abiraterone. The breakthrough will help doctors to prescribe the drug to more men and avoid spending on other unnecessary treatments.
"The natural history of advanced and aggressive prostate cancer is highly variable and now with better treatments, the risk of cancer relapse can be significantly reduced," said Professor Gert Attard, co-lead of the study.
"This study shows, in a very large cohort of patients, that novel AI algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise overtreatment whilst maximising the chance of cure."
The test uses AI to study images of tumours and examine features invisible to the human eye. The team trialled the test on biopsy images from more than 1,000 men with high-risk prostate cancer that had not spread.
Using the new AI test, researchers found that abiraterone given alongside standard hormone therapy almost halves the risk of death for approximately 25 per cent of men with prostate cancer.
Notably, abiraterone works by inhibiting the production of testosterone in all tissues throughout the body, including the tumour.
"This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone - hormone therapy and radiotherapy," said Professor Nick James, co-lead of the trial.
"I truly hope that this new research, showing precisely who needs the drug to live well for longer will lead to NHS England reviewing their decision to fund abiraterone for high-risk prostate cancer that has not spread."
The trial results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 hours ago
- Time of India
Evidence of CAR T-cell therapy against cancers presented at US conference
New Delhi: Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials , 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. "In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote. They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours". In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer ". The phase-1 trial involved 18 patients with glioblastoma who received the treatment. "Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI
The Hindu
16 hours ago
- The Hindu
Evidence of CAR T-cell therapy against cancers presented at US conference
Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells – a type of immune cell – to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials, 156 patients with advanced gastric or gastro-oesophageal junction cancer – and who were resistant to 'at least two previous lines of treatment' – were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' – a CAR T-cell therapy -- showed 'encouraging activity' in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. 'In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients,' the authors wrote. They added that it is the 'first randomised controlled study of a CAR T-cell therapy in solid tumours'. In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy 'shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer'. The phase-1 trial involved 18 patients with glioblastoma who received the treatment. 'Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease,' the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal.
Economic Times
a day ago
- Economic Times
AstraZeneca breast cancer medicine slows disease by over six months
Agencies Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment. Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients. Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
